Chile Pharmaceuticals & Healthcare Q2 2018
The appearance of Chile on the 2018 PhRMA priority list highlights the continued regulatory concerns in Chile. Thepartial solutions and slow implementation of regulatory regulations will continue to pose downside risks to the pharmaceuticalindustry. The adherence to the conditions in the Chile-US Free Trade Agreement will pose upside risks to the intellectual propertyenvironment.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook